Long-term methimazole therapy in Graves’ hyperthyroidism and adverse reactions: a Danish multicenter study
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 569 KB, PDF document
Purpose: In this prospective multicenter study with patients newly diagnosed with Graves’ hyperthyroidism (GH), we studied the timing and characteristics of adverse drug reactions in patients treated with anti-thyroid drugs (ATD) for up to 48 months. Methods: Patients with GH were treated with ATD until remission and hereafter with a low-dose regime to keep the patients in remission. The patients were followed with blood samples and recording of adverse events approximately every second month for the first 2 years and every third month for the following 2 years. Results: We included 208 patients and the patients were treated for a median of 22 (range: 0.5–49) months. Ten percent of the patients experienced adverse drug reactions and 75% of the cases occurred during the first 6 months. After 24 months, the methimazole dose was lowered to 5 mg/day, and after this time point, no further adverse drug reactions were recorded. Skin reactions were the most prominent reaction, comprising 68% of the registered reactions, and no hepatic and bonemarrow affection was recorded. Conclusion: With this study, we report the frequency, timing of occurrence, and characteristics of adverse drug reactions when treating GH with the ATD drug methimazole for up to 48 months. Long-term low-dose methimazole treatment can be a cost-effective and straightforward treatment option if adverse drug reactions such as severe hepatic and bone marrow affection are kept in mind.
Original language | English |
---|---|
Article number | e220031 |
Journal | European Thyroid Journal |
Volume | 11 |
Issue number | 3 |
Number of pages | 6 |
ISSN | 2235-0640 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
© 2022 The authors Published by Bioscientifica Ltd.
- anti-thyroid drugs adverse drug, Graves’ disease, Graves’ hyperthyroidism, hyperthyroidism, reactions adverse events, thyrotoxicosis, TSH-receptor anti-bodies
Research areas
ID: 328731015